All Professionals
Overview
Maxine Jin is a China associate in the Corporate Department at Paul Hastings and is based in the firm’s Shanghai office. Her practice focuses on initial public offerings and transactions related to the Hong Kong capital market.
She is fluent in English and Mandarin Chinese.
Education
- East China University of Political Science and Law, LL.B, 2025
Representations
- Guangdong Dtech Technology Co., Ltd., a leading integrated provider of precision manufacturing solutions for the global PCB fabrication value chain, on its HK$4.8 billion global offering and listing of H shares on the Main Board of the Hong Kong Stock Exchange. *
- Morgan Stanley and CLSA Limited as the placing agents on the HK$472 million placing of new H shares of GenFleet Therapeutics (Shanghai), Inc., a biopharmaceutical company focused on developing innovative treatment solutions in the fields of oncology, autoimmune and inflammatory diseases, on the Main Board of the Hong Kong Stock Exchange. *
- WuXi AppTec Co., Ltd., a global leading pharmaceutical R&D and manufacturing services company, on its issuance of RMB6.78 billion U.S. dollar-settled zero-coupon convertible bonds due 2027, with the bonds listed on the Vienna Stock Exchange. *
- Guangdong Huayan Robotics Co., Ltd., a leading collaborative robotics company in China, on its HK$1.58 billion global offering and listing under Chapter 18C on the Main Board of the Hong Kong Stock Exchange. *
- Star Sports Medicine Co., Ltd., a leading sports medicine medical device company in China, on its HK$830 million global offering and listing on the Main Board of the Hong Kong Stock Exchange.*
- B&K Corporation Limited, a biopharmaceutical company focused on developing protein-based therapies for wound healing, on its HK$674 million global offering and listing under Chapter 18A on the Main Board of the Hong Kong Stock Exchange. *
* including projects involved in prior to joining Paul Hastings